Lindsay Burns

Last updated

Lindsay Burns
Personal information
Born1965 (age 58–59)
Big Timber, Montana, U.S.
Medal record
Women's rowing
Representing Flag of the United States (23px).png  United States
Olympic Games
Silver medal icon (S initial).svg 1996 Atlanta Lwt double sculls
World Rowing Championships
Gold medal icon (G initial).svg 1987 Copenhagen Lwt four
Silver medal icon (S initial).svg 1990 Tasmania Lwt double sculls
Silver medal icon (S initial).svg 1991 Vienna Lwt double sculls
Bronze medal icon (B initial).svg 1994 Indianapolis Lwt double sculls

Lindsay H. Burns (born 1965) is an American neuroscientist and rower who won a silver medal at the 1996 Summer Olympics. [1] She was a senior vice president of the pharmaceutical company Cassava Sciences [2] until July 2024 and married to its CEO Remi Barbier.

Contents

As of July 2022, Cassava Sciences and papers co-authored by Burns were under investigation; [3] [4] co-author Hoau-Yan Wang was indicted for fraud in 2024 and Cassava denies any wrongdoing. [5] Burns and Barbier (president and chief executive officer of Cassava) [6] [7] [8] [9] abruptly resigned in 2024 following Wang's indictment. [10] [11]

The U.S. Securities and Exchange Commission (SEC) filed charges in September 2024 against Cassava, Barbier, Burns and Wang with allegations including violations of "antifraud provisions of the federal securities laws" and "reporting provisions of the federal securities laws". The parties did not admit wrongdoing, but a settlement of the SEC charges, pending court approval, would fine Cassava $US40 million, Barbier $175,000, Burns $85,000 and Wang $50,000. [12] [13]

Personal life

Burns was born in 1965 [14] and raised in Big Timber, Montana. [15] She graduated from Harvard University in 1987. [15] In 1991, she obtained a PhD in neuroscience from University of Cambridge [15] on a thesis titled Functional interactions of limbic afferents to the striatum and mesolimbic dopamine in reward-related processes, [16] which was supervised by Barry Everitt and Trevor Robbins. [17] [18]

Burns worked as a research fellow in psychobiology at McLean Hospital in Belmont, Massachusetts. [15] She joined Cassava Sciences in 2002 and became senior vice president of neuroscience in 2021. [19]

Burns is married to Remi Barbier, the former CEO [10] [11] and founder of Cassava Sciences. [9] [7] [20]

Rowing career

Burns started competitive rowing soon after entering Harvard. [15] In 1987, she rowed in the Radcliffe varsity crew and won the Eastern Association of Women's Rowing Colleges (EAWRC) championship that awarded her the Ivy title and the EAWRC League title. [9] She was part of the US rowing team from 1987 and from 1990 to 1996. Competing in the lightweight category at six World Rowing Championships, she won four medals: gold at the 1987; silvers in the double in 1990 and 1991; and bronze in the double in 1994. She won a silver medal at the 1995 Pan American Games competing in the quad sculls (heavyweight) category [1] and she won the European Rowing Championships at Lucerne in 1995 with Teresa Bell. [21] She was an alternate rower at the 1992 Summer Olympics in Barcelona, Spain.[ citation needed ]

She teamed up again with Teresa Bell at the 1996 Summer Olympics in Atlanta, United States, and won a silver medal in the Lightweight Double Sculls. [1] In 2006, she was inducted into the Harvard Sports Hall of Fame. [9] In 2016, she was inducted into the National Rowing Foundation Hall of Fame. [22]

Scientific works

Burns's first research was on the effect of neurokinin A on brain functions in rats. Her first paper in 1988, written with Ann E. Kelley, reported that neurokinin A in the ventral tegmental area modifies dopamine circuits to induce behavioral changes. [23] She continued her PhD research on the role of dopamine and the limbic system. [17] [18] [16] [24] [25] During her post-doc at McLean Hospital, she focused on neurodegenerative diseases, specifically, transplantation of pig neural cells into rat brain as a possible treatment of Parkinson's or Huntington's disease. [26] Further research indicated possible use in humans. [27] While working for a biotech company later acquired by Elan Pharmaceuticals, she published the effects of ziconotide in a rat model of spinal cord ischemia. [28]

In 2005, she published a series of papers on Oxytrex and related research with ultra-low doses of certain (opioid antagonists) to enhance analgesia and prevent opioid-induced hyperalgesia, opioid tolerance and substance dependence. [29] [30] [31] [32]

Since 2006, Burns collaborated with Hoau-Yan Wang at the City University of New York, [33] who had been investigating Alzheimer's disease. Burns and Wang wrote that FLNA was a critical protein in enabling Abeta42's signaling through the alpha 7 nicotinic acetylcholine receptor to induce Alzheimer's disease pathology (the publication has an expression of concern). [34] [35] [36]

FLNA, simufilam and Alzheimer's disease

In 2008, Burns, Wang and Maya Frankfurt published in PLOS One a (later retracted) finding that the opioid antagonists naloxone and naltrexone bind with ultra-high affinity to FLNA to prevent mu opioid receptor excitatory signaling. [37] Burns and Wang published (now retracted) the binding site on FLNA and the activation of CREB by opioid receptor – Gs coupling in the same journal the next year. [38] FLNA is a cytoplasmic protein that maintains normal cell shape and division. In 2010, Burns and Wang announced a novel analgesic" which they named PTI-609 (PTI for Pain Therapeutics, Inc., the former name of Cassava Sciences) and stated that the molecule binds to FLNA as well as activating mu opioid receptors. [39]

In 2012, they published in The Journal of Neuroscience (now with an expression of concern) a novel compound PTI-125 that binds to FLNA similarly to naloxone and naltrexone. [40] With PTI-125, they stated that FLNA aberrantly links to the alpha 7 nicotinic receptor, enabling signaling of Abeta42 to hyperphosphorylate tau. [35] [40]

In 2017, they stated in Neurobiology of Aging (now with an expression of concern) that the FLNA in Alzheimer's disease transgenic mice and human postmortem brain tissue has an altered conformation (based on a shift in isoelectric focusing) and that PTI-125 binding to altered FLNA restores its normal shape, thereby reducing tau hyperphosphorylation, amyloid deposits and tau-containing lesions in the brains of the mice. [41] [42] The United States Adopted Names (USAN) gave the drug name for PTI-125 as simufilam in 2020; [43] as of 2022, it is in Phase III clinical trials.

Research controversies

As of July 2022, Cassava Sciences and papers published by Burns and Wang were under investigation by the DOJ; Cassava denies any wrongdoing. [44] [45] [46] The U.S. Securities and Exchange Commission (SEC), the U.S. National Institutes of Health (NIH), and City University of New York (CUNY) were also investigating allegations of manipulated data. [46] According to The Wall Street Journal, the CUNY report stated that Burns shared with Wang some responsibility "for errors and misconduct". [47] [48] In June 2024, Wang was indicted by the United States Department of Justice (DOJ) for fraud and charged with falsifying data on $16 million in grant applications to the NIH related to the Alzheimer's drug in development, simufilam. [5] [49] [50] [51]

In September, the SEC charged Cassava, Barbier and Burns for "misleading statements ... made in September 2020 about the results of a phase two clinical trial for Cassava's purported drug treatment for Alzheimer's", and charged Wang for "manipulating the trial results". [12] [52] [53] According to Reuters, the company "failed to disclose that a full set of patient data actually showed 'no measurable cognitive improvement in the patients' episodic memory'." [12] The charges filed in the United States District Court for the Western District of Texas alleged that Cassava violated "antifraud provisions of the federal securities laws" and "reporting provisions of the federal securities laws" and the SEC stated in a press release that "without admitting or denying the allegations, Cassava, Barbier, and Burns ... agreed to pay civil penalties of $40 million, $175,000, and $85,000, respectively. Barbier and Burns agreed to be subject to officer-and-director bars of three and five years, respectively." [52] [12] [13] The settlement must be approved by the U.S. District Court. [13] According to Science journal's Piller, the SEC charged that Burns "'negligently failed to fully disclose' that she had removed data from 40% of the volunteers in a phase 2 simufilam clinical trial after learning which ones received simufilam or the placebo." [13]

Related Research Articles

<span class="mw-page-title-main">Naltrexone</span> Medication

Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use or opioid use disorder by reducing cravings and feelings of euphoria associated with substance use disorder. It has also been found effective in the treatment of other addictions and may be used for them off-label. An opioid-dependent person should not receive naltrexone before detoxification. It is taken orally or by injection into a muscle. Effects begin within 30 minutes, though a decreased desire for opioids may take a few weeks to occur.

<span class="mw-page-title-main">Huperzine A</span> Chemical compound

Huperzine A is a naturally-occurring sesquiterpene alkaloid compound found in the firmoss Huperzia serrata and in varying quantities in other food Huperzia species, including H. elmeri, H. carinat, and H. aqualupian. Huperzine A has been investigated as a treatment for neurological conditions such as Alzheimer's disease, but a 2013 meta-analysis of those studies concluded that they were of poor methodological quality and the findings should be interpreted with caution. Huperzine A inhibits the breakdown of the neurotransmitter acetylcholine (ACh) by the enzyme acetylcholinesterase. It is also an antagonist of the NMDA-receptor. It is commonly available over the counter as a nutritional supplement and marketed as a memory and concentration enhancer.

<span class="mw-page-title-main">Opioid antagonist</span> Receptor antagonist that acts on one or more of the opioid receptors

An opioid antagonist, or opioid receptor antagonist, is a receptor antagonist that acts on one or more of the opioid receptors.

Low-dose naltrexone (LDN) refers to daily naltrexone dosages that are roughly one-tenth of the standard opioid addiction treatment dosage. Most published research suggests a daily dosage of 4.5 mg, but this can vary by a few milligrams. Low-dose naltrexone has been studied for the treatment of multiple chronic pain disorders including fibromyalgia, multiple sclerosis, Crohn’s disease, and complex regional pain syndrome.

<span class="mw-page-title-main">Nalmefene</span> Opioid antagonist

Nalmefene, sold under the brand name Revex among others, is a medication that is used in the treatment of opioid overdose and alcohol dependence. Nalmefene belongs to the class of opioid antagonists and can be taken by mouth, administered by injection, or delivered through nasal administration.

<span class="mw-page-title-main">NMDA receptor antagonist</span> Class of anesthetics

NMDA receptor antagonists are a class of drugs that work to antagonize, or inhibit the action of, the N-Methyl-D-aspartate receptor (NMDAR). They are commonly used as anesthetics for humans and animals; the state of anesthesia they induce is referred to as dissociative anesthesia.

μ-opioid receptor Protein-coding gene in the species Homo sapiens, named for its ligand morphine

The μ-opioid receptors (MOR) are a class of opioid receptors with a high affinity for enkephalins and beta-endorphin, but a low affinity for dynorphins. They are also referred to as μ(mu)-opioid peptide (MOP) receptors. The prototypical μ-opioid receptor agonist is morphine, the primary psychoactive alkaloid in opium and for which the receptor was named, with mu being the first letter of Morpheus, the compound's namesake in the original Greek. It is an inhibitory G-protein coupled receptor that activates the Gi alpha subunit, inhibiting adenylate cyclase activity, lowering cAMP levels.

<span class="mw-page-title-main">Toll-like receptor 4</span> Cell surface receptor found in humans

Toll-like receptor 4 (TLR4), also designated as CD284, is a key activator of the innate immune response and plays a central role in the fight against bacterial infections. TLR4 is a transmembrane protein of approximately 95 kDa that is encoded by the TLR4 gene.

<span class="mw-page-title-main">Methylnaltrexone</span> Medication in the treatment for Opioid-Induced Constipation

Methylnaltrexone, used in form of methylnaltrexone bromide, is a medication that acts as a peripherally acting μ-opioid receptor antagonist that acts to reverse some of the side effects of opioid drugs such as constipation without significantly affecting pain relief or precipitating withdrawals. Because MNTX is a quaternary ammonium cation, it cannot cross the blood–brain barrier, and so has antagonist effects throughout the body, counteracting effects such as itching and constipation, but without affecting opioid effects in the brain such as pain relief. However, since a significant fraction of opioid analgesia can be mediated by opioid receptors on peripheral sensory neurons, particularly in inflammatory conditions such as arthritis, traumatic or surgical pain, MNTX may increase pain under such circumstances.

<span class="mw-page-title-main">FLNA</span> Protein-coding gene in humans

Filamin A, alpha (FLNA) is a protein that in humans is encoded by the FLNA gene.

<span class="mw-page-title-main">7-Spiroindanyloxymorphone</span> Chemical compound

7-Spiroindanyloxymorphone (SIOM) is a drug that is used in scientific research. It is a selective δ-opioid agonist. It is a derivative of oxymorphone.

<span class="mw-page-title-main">Opioid overdose</span> Toxicity due to excessive consumption of opioids

An opioid overdose is toxicity due to excessive consumption of opioids, such as morphine, codeine, heroin, fentanyl, tramadol, and methadone. This preventable pathology can be fatal if it leads to respiratory depression, a lethal condition that can cause hypoxia from slow and shallow breathing. Other symptoms include small pupils and unconsciousness; however, its onset can depend on the method of ingestion, the dosage and individual risk factors. Although there were over 110,000 deaths in 2017 due to opioids, individuals who survived also faced adverse complications, including permanent brain damage.

<span class="mw-page-title-main">Naltrexone/bupropion</span> Medication for treatment of obesity

Naltrexone/bupropion, sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity. It contains naltrexone, an opioid antagonist, and bupropion, an aminoketone atypical antidepressant. It is taken by mouth. Both medications have individually shown some evidence of effectiveness in weight loss, and the combination has been shown to have some synergistic effects on weight.

<span class="mw-page-title-main">(+)-Naloxone</span> Drug

(+)-Naloxone (dextro-naloxone) is a drug which is the opposite enantiomer of the opioid antagonist drug (−)-naloxone. Unlike (−)-naloxone, (+)-naloxone has no significant affinity for opioid receptors, but instead has been discovered to act as a selective antagonist of Toll-like receptor 4. This receptor is involved in immune system responses, and activation of TLR4 induces glial activation and release of inflammatory mediators such as TNF-α and Interleukin-1.

<span class="mw-page-title-main">Samidorphan</span> Opioid antagonist

Samidorphan is an opioid antagonist that in the form of olanzapine/samidorphan is used in the treatment of schizophrenia and bipolar disorder. Samidorphan reduces the weight gain associated with olanzapine. Samidorphan is taken by mouth.

David S. Bredt is an American molecular neuroscientist.

<span class="mw-page-title-main">6β-Naltrexol</span> Chemical compound

6β-Naltrexol, or 6β-hydroxynaltrexone, is a peripherally-selective opioid receptor antagonist related to naltrexone. It is a major active metabolite of naltrexone formed by hepatic dihydrodiol dehydrogenase enzymes. With naltrexone therapy, 6β-naltrexol is present at approximately 10- to 30-fold higher concentrations than naltrexone at steady state due to extensive first-pass metabolism of naltrexone into 6β-naltrexol. In addition to being an active metabolite of naltrexone, 6β-naltrexol was itself studied for the treatment of opioid-induced constipation. It was found to be effective and well-tolerated, and did not precipitate opioid withdrawal symptoms or interfere with opioid pain relief, but development was not further pursued.

<span class="mw-page-title-main">Nalodeine</span> Chemical compound

Nalodeine, also known more commonly as N-allylnorcodeine, is an opioid antagonist that was never marketed but is notable as the first opioid antagonist to be discovered. It was first reported in 1915 and was found to block the effects of morphine in animals. This was followed by the clinical introduction of nalorphine (N-allylnormorphine) in 1954, naloxone (N-allyloxymorphone) in 1960, and naltrexone (N-methylcyclopropyloxymorphone) in 1963. Nalmefene (6-desoxy-6-methylene-naltrexone), another structurally related opioid antagonist derivative, was also subsequently introduced, in 1996. In animals, nalodeine both reverses morphine- and heroin-induced respiratory depression and acts as a respiratory stimulant in its own right. Similarly to nalorphine, nalodeine has also been found to act as an agonist of the κ-opioid receptor.

<span class="mw-page-title-main">Simufilam</span> Experimental drug for Alzheimers disease

Simufilam (PTI-125) is an experimental medication for the treatment of Alzheimer's disease. It is being developed by the American pharmaceutical firm Cassava Sciences. The drug is in phase III clinical trials as of October 2023. There are two phase III clinical studies: RETHINK-ALZ, a 52-week trial, is set to complete in 2024, and REFOCUS-ALZ, spanning 76 weeks, is projected to finish in 2025.

Cassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was founded in 1998 by Remi Barbier as Pain Therapeutics, Inc., changing its name in 2019.

References

  1. 1 2 3 "Biography: Lindsay Burns". Olympics. International Olympic Committee. Retrieved May 2, 2022.
  2. ↑ Keown, Alex (April 19, 2022). "Cassava Faces Renewed Speculation Over Experimental Alzheimer's Drug". BioSpace. Retrieved May 9, 2022.
  3. ↑ Mandavilli, Apoorva (April 18, 2022). "Scientists Question Data Behind an Experimental Alzheimer's Drug". The New York Times. ISSN   0362-4331 . Retrieved April 28, 2022.
  4. ↑ "The Cassava Sciences saga: Short sellers, 'gaming' the FDA, and the damaging ripple effects".
  5. 1 2 "Cassava Sciences Issues Statement on Former Science Advisor" (Press release). Cassava Sciences. June 28, 2024. Retrieved June 29, 2024.
  6. ↑ "Management". Cassava Sciences. Archived from the original on June 28, 2024. Retrieved July 18, 2024.
  7. 1 2 Keefe, Patrick Radden (January 15, 2022). "Jordan Thomas's Army of Whistle-Blowers" . The New Yorker . Archived from the original on July 22, 2022. Retrieved April 29, 2022.
  8. ↑ Feuerstein, Adam (April 5, 2022). "Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer's drug studies". Stat . Retrieved April 30, 2022.
  9. 1 2 3 4 "Lindsay Burns Barbier '87". www.harvardvarsityclub.org. Archived from the original on June 2, 2022. Retrieved May 2, 2022.
  10. 1 2 Feuerstein, Adam (July 17, 2024). "With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer's disease world". STAT news. Retrieved July 18, 2024.
  11. 1 2 "Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives" (Press release). Cassava Sciences. July 17, 2024. Retrieved July 18, 2024.
  12. 1 2 3 4 "Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims". Reuters. September 26, 2024. Retrieved October 1, 2024.
  13. 1 2 3 4 Piller, Charles (September 30, 2024). "Company misled investors on possible Alzheimer's drug, SEC charges". Science . doi:10.1126/science.adt5694. PMID   39361735. Archived from the original on October 1, 2024. Retrieved October 1, 2024.
  14. ↑ "Lindsay Burns". World Rowing.
  15. 1 2 3 4 5 "Harvard at the Olympics". Harvard Magazine. Retrieved May 3, 2022.
  16. 1 2 Burns, Lindsay H. (1991). Functional interactions of limbic afferents to the striatum and mesolimbic dopamine in reward-related processes (Ph.D. thesis). University of Cambridge. OCLC   556753196.
  17. 1 2 Burns, L; Robbins, T; Everitt, B (1993). "Differential effects of excitotoxic lesions of the basolateral amygdala, ventral subiculum and medial prefrontal cortex on responding with conditioned reinforcement and locomotor activity potentiated by intra-accumbens infusions ofd-amphetamine". Behavioural Brain Research. 55 (2): 167–183. doi:10.1016/0166-4328(93)90113-5. PMID   8357526. S2CID   4032314.
  18. 1 2 Burns, Lindsay H.; Everitt, Barry J.; Kelley, Ann E.; Robbins, Trevor W. (1994). "Glutamate-dopamine interactions in the ventral striatum: role in locomotor activity and responding with conditioned reinforcement". Psychopharmacology. 115 (4): 516–528. doi:10.1007/BF02245576. PMID   7871097. S2CID   28351013.
  19. ↑ "Lindsay H Burns, Cassava Sciences Inc: Profile and Biography". Bloomberg.com. Retrieved May 3, 2022.
  20. ↑ Feuerstein, Adam (April 5, 2022). "Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer's drug studies". STAT. Retrieved April 30, 2022.
  21. ↑ "Rowing News". July 16–29, 1995.
  22. ↑ "The National Rowing Foundation Announces the 2016 Inductees to the National Rowing Hall of Fame". January 26, 2016.
  23. ↑ Burns, Lindsay H.; Kelley, Ann E. (1988). "Neurokinin-α injected into the ventral tegmental area elicits a dopamine-dependent behavioral activation in the rat". Pharmacology Biochemistry and Behavior. 31 (2): 255–263. doi:10.1016/0091-3057(88)90343-7. PMID   2469085. S2CID   20941335.
  24. ↑ Burns, Lindsay H.; Annett, Lucy; Kelly, Ann E.; Everitt, Barry J.; Robbins, Trevor W. (1996). "Effects of lesions to amygdala, ventral subiculum, medial prefrontal cortex, and nucleus accumbens on the reaction to novelty: Implications for limbic—striatal interactions". Behavioral Neuroscience. 110 (1): 60–73. doi:10.1037/0735-7044.110.1.60. ISSN   1939-0084. PMID   8652073.
  25. ↑ Parkinson, John A.; Olmstead, Mary C.; Burns, Lindsay H.; Robbins, Trevor W.; Everitt, Barry J. (1999). "Dissociation in Effects of Lesions of the Nucleus Accumbens Core and Shell on Appetitive Pavlovian Approach Behavior and the Potentiation of Conditioned Reinforcement and Locomotor Activity byd-Amphetamine". Journal of Neuroscience. 19 (6): 2401–2411. doi:10.1523/JNEUROSCI.19-06-02401.1999. PMC   6782569 . PMID   10066290.
  26. ↑ Isacson, Ole; Deacon, Terrence W.; Pakzaban, Peyman; Galpern, Wendy R.; Dinsmore, Jonathan; Burns, Lindsay H. (1995). "Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres". Nature Medicine. 1 (11): 1189–1194. doi:10.1038/nm1195-1189. PMID   7584993. S2CID   7344970.
  27. ↑ Galpern, Wendy R.; Burns, Lindsay H.; Deacon, Terrence W.; Dinsmore, Jonathan; Isacson, Ole (1996). "Xenotransplantation of Porcine Fetal Ventral Mesencephalon in a Rat Model of Parkinson's Disease: Functional Recovery and Graft Morphology". Experimental Neurology. 140 (1): 1–13. doi: 10.1006/exnr.1996.0109 . PMID   8682173. S2CID   23945411.
  28. ↑ Burns, Lindsay H.; Jin, Zhen; Bowersox, S.Scott (1999). "The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia". Journal of Vascular Surgery. 30 (2): 334–343. doi: 10.1016/S0741-5214(99)70145-X . PMID   10436454.
  29. ↑ Chindalore, Vishala L.; Craven, Richard A.; Yu, K. Peony; Butera, Peter G.; Burns, Lindsay H.; Friedmann, Nadav (2005). "Adding Ultralow-Dose Naltrexone to Oxycodone Enhances and Prolongs Analgesia: A Randomized, Controlled Trial of Oxytrex". The Journal of Pain. 6 (6): 392–399. doi: 10.1016/j.jpain.2005.01.356 . PMID   15943961.
  30. ↑ Olmstead, Mary C.; Burns, Lindsay H. (2005). "Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats". Psychopharmacology. 181 (3): 576–581. doi:10.1007/s00213-005-0022-7. PMID   16010543. S2CID   13270740.
  31. ↑ Leri, Francesco; Burns, Lindsay H. (2005). "Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats". Pharmacology Biochemistry and Behavior. 82 (2): 252–262. doi:10.1016/j.pbb.2005.08.008. PMID   16182352. S2CID   25513761.
  32. ↑ Burns, Lindsay H.; Vanderah, Todd W.; Wang, Hoau-Yan (2009), Dean, Reginald L.; Bilsky, Edward J.; Negus, S. Stevens (eds.), "Ultra-Low-Dose Opioid Antagonists Enhance Opioid Analgesia and Reduce Tolerance", Opiate Receptors and Antagonists, Totowa, NJ: Humana Press, pp. 3–17, doi:10.1007/978-1-59745-197-0_1, ISBN   978-1-58829-881-2 , retrieved May 3, 2022
  33. ↑ Wang, Hoau-Yan; Burns, Lindsay H. (2006). "Gβγ that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein". Journal of Neurobiology. 66 (12): 1302–1310. doi:10.1002/neu.20286. PMID   16967511.
  34. ↑ Wang, Hoau-Yan; Bakshi, Kalindi; Frankfurt, Maya; Stucky, Andres; Goberdhan, Marissa; Shah, Sanket M.; Burns, Lindsay H. (2012). "Reducing Amyloid-Related Alzheimer's Disease Pathogenesis by a Small Molecule Targeting Filamin A". J Neurosci. 32 (29): 9773–9784. doi:10.1523/JNEUROSCI.0354-12.2012. PMC   6621293 . PMID   22815492. S2CID   9933756. (This paper currently has an expression of concern, see doi:10.1523/JNEUROSCI.2306-21.2021, PMID   34921050,  Retraction Watch)
  35. 1 2 Burns, Lindsay H.; Wang, Hoau-Yan (2017). "Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer's disease". Neuroimmunology and Neuroinflammation. 4 (12): 263–271. doi:10.20517/2347-8659.2017.50. PMC   8294116 . PMID   34295950.
  36. ↑ Wang, Hoau-Yan; Pei, Zhe; Xu, Qiang; Brunelle, Lynn A; Burns, Lindsay H.; Thornton, George Ben (2021). "SavaDx, a novel plasma biomarker to detect Alzheimer's disease, confirms mechanism of action of simufilam". Alzheimer's & Dementia. 17 (S5): online. doi:10.1002/alz.054385. S2CID   245570217.
  37. ↑ Wang, Hoau-Yan; Frankfurt, Maya; Burns, Lindsay H. (February 6, 2008). "High-affinity naloxone binding to filamin a prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence". PLOS ONE. 3 (2): e1554. Bibcode:2008PLoSO...3.1554W. doi: 10.1371/journal.pone.0001554 . PMC   2212716 . PMID   18253501. (Retracted, see doi:10.1371/journal.pone.0266627, PMID   35353861,  Retraction Watch)
  38. ↑ Wang, Hoau-Yan; Burns, Lindsay H. (2009). "Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine". PLOS ONE. 4 (1): e4282. Bibcode:2009PLoSO...4.4282W. doi: 10.1371/journal.pone.0004282 . ISSN   1932-6203. PMC   2628740 . PMID   19172190. (Retracted, see doi:10.1371/journal.pone.0266629, PMID   35353864,  Retraction Watch)
  39. ↑ Burns, Lindsay H.; Wang, Hoau-Yan (2010). "PTI-609: A Novel Analgesic that Binds Filamin A to Control Opioid Signaling". Recent Patents on CNS Drug Discovery. 5 (3): 210–220. doi:10.2174/157488910793362386. PMID   20726836.
  40. 1 2 Wang, H.-Y.; Bakshi, K.; Frankfurt, M.; Stucky, A.; Goberdhan, M.; Shah, S. M.; Burns, L. H. (2012). "Reducing Amyloid-Related Alzheimer's Disease Pathogenesis by a Small Molecule Targeting Filamin A". Journal of Neuroscience. 32 (29): 9773–9784. doi:10.1523/JNEUROSCI.0354-12.2012. PMC   6621293 . PMID   22815492. (This paper currently has an expression of concern, see doi:10.1523/JNEUROSCI.2306-21.2021, PMID   34921050,  Retraction Watch)
  41. ↑ Wang, Hoau-Yan; Lee, Kuo-Chieh; Pei, Zhe; Khan, Amber; Bakshi, Kalindi; Burns, Lindsay H. (2017). "PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis". Neurobiology of Aging. 55: 99–114. doi:10.1016/j.neurobiolaging.2017.03.016. PMID   28438486. S2CID   207163555. (This paper currently has an expression of concern, see doi:10.1016/j.neurobiolaging.2022.03.012)
  42. ↑ Toniolo, Sofia; Sen, Arjune; Husain, Masud (2020). "Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease". International Journal of Molecular Sciences. 21 (23): 9318. doi: 10.3390/ijms21239318 . PMC   7730926 . PMID   33297460.
  43. ↑ "Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned the Chemical Drug Name 'sumifilam' by USAN". Global Newswire (Press release). Cassava Sciences. August 24, 2020. Retrieved May 3, 2022.
  44. ↑ Taylor, Marisa; Spector, Mike (July 27, 2022). "Exclusive: Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say". Reuters. Retrieved July 31, 2022.
  45. ↑ "Cassava Sciences Responds to Media Reports" (Press release). Cassava Sciences. July 27, 2022. Retrieved August 16, 2022.
  46. 1 2 Michaels, Dave; Walker, Joseph (November 17, 2021). "SEC Investigating Cassava Sciences, Developer of Experimental Alzheimer's Drug". Wall Street Journal. ISSN   0099-9660 . Retrieved April 29, 2022.
  47. ↑ Piller C (October 12, 2023). Co-developer of Cassava's potential Alzheimer's drug cited for 'egregious misconduct' (Report). Science. doi:10.1126/science.adl3444.
  48. ↑ Subbaraman N, Walker J (October 13, 2023). "Cassava Sciences Adviser Found to Have Committed 'Egregious Misconduct'; Scientist, who is a City University of New York professor, didn't provide school investigators with data or records supporting his research". Wall Street Journal. ProQuest   2876611078.
  49. ↑ Mandavilli, Apoorva (June 28, 2024). "Embattled Alzheimer's Researcher Is Charged With Fraud". The New York Times. Retrieved June 29, 2024.
  50. ↑ Wosen, Jonathan (June 28, 2024). "Cassava Sciences collaborator charged with defrauding NIH in grants supporting its Alzheimer's drug". Stat News. Retrieved June 29, 2024.
  51. ↑ Walker, Joseph (June 28, 2024). "Cassava Sciences Adviser Indicted on Fraud Charges". The Wall Street Journal. Retrieved June 29, 2024.
  52. 1 2 "SEC Charges Cassava Sciences, Two Former Executives for Misleading Claims About Alzheimer's Clinical Trial" (Press release). U.S. Securities and Exchange Commission. September 26, 2024. Retrieved October 1, 2024.
  53. ↑ "Cassava Sciences, Inc., Remi Barbier, and Lindsay Burns". U.S. Securities and Exchange Commission. September 26, 2024. Retrieved October 1, 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.